Structural analysis involved creating, to our knowledge, the first computational model of IPE bound to FADS1. We also generated molecular dynamic simulations which showed IPE remains in the binding pocket for >300 ns. These models suggest stable binding modes of IPE to FADS1. 5/n

Next, we used two-sample Mendelian randomization to proxy the therapeutic effects of these medications on MASLD risk. We found that icosapent ethyl (IPE), proxied by FADS1/FADS2 expression, and fingolimod, proxied by S1PR2 expression, have protective effects against MASLD.

Millions of Americans have MASLD, but there are currently a limited number of treatment options. We developed a genome-informed drug repurposing approach, which integrates genetic, molecular, and pharmacological data, to identify new treatments for MASLD. 2/n

Excited to share our work on drug repurposing for metabolic dysfunction-associated steatotic liver disease this week at the Keystone Symposia meeting. I am also so honored and grateful to receive a scholarship award!